NCT01212341

Allogeneic Natural Killer (NK) Cell Therapy in Patients With Lymphoma or Solid Tumor

A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.

Conditions

• Malignant Lymphomas
• Solid Tumors

Interventions

Type	Name	Description
BIOLOGICAL	Allogeneic NK cells

Timeline

• Start date: 2010-09-01
• Primary completion: 2012-08-01
• Completion: 2013-03-01
• First posted: 2010-09-30
• Last updated: 2013-08-19

Locations

1 site across 1 country: South Korea